FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078757541> ?p ?o ?g. }

• W2078757541 endingPage "1432" @default.
• W2078757541 startingPage "1428" @default.
• W2078757541 abstract "Background. OKT3 is often used as primary treatment for acute renal allograft rejection. In a retrospective study, we sought to determine the efficacy of OKT3 as a first-line agent in reversing histologically confirmed acute renal allograft rejection. Methods. Patients with mild to moderate, moderate, or severe acute cellular and acute vascular rejection who had not received any other anti-rejection treatment were included in this analysis. A total of 88 patients, who received OKT3 between 1987 and 1995, fulfilled these criteria. Result. Seventy of these patients were renal transplant recipients, and 18 were combined kidney and pancreas transplant recipients. The median time to the diagnosis of rejection from transplantation was 32 days (range, 6 days to 13 years). On histology, 6 were graded as mild to moderate, 36 as moderate, 29 as moderate to severe, and 17 as severe rejection. The mean baseline serum creatinine was 1.62 mg/dl (range, 0.7-10.1 mg/dl), and the mean serum creatinine at the time of diagnosis of rejection was 2.60 mg/dl (range, 1.4-12.7 mg/dl) (P=<0.0001). The mean duration of OKT3 treatment was 11.2 days (range, 8-18 days). The mean serum creatinine at the end of OKT3 treatment was 1.73 mg/dl (range, 0.6-5.0 mg/dl;P=0.24 compared with baseline serum creatinine). Rejection was reversed in 86 (98%) patients. Graft survival at 1 year after OKT3 therapy was 87.5% (77 of 88). At a mean follow-up of 38 months, 8 patients had died and 26 grafts were lost. The mean serum creatinine level in the 64 patients with a functioning graft was 1.76 mg/dl (range, 0.8-4.0 mg/dl) at the last follow-up. Conclusion. OKT3 when utilized as first-line therapy reversed 98% of the acute rejection episodes, with a 1-year post-OKT3 graft survival of 87.5%." @default.
• W2078757541 created "2016-06-24" @default.
• W2078757541 creator A5026208455 @default.
• W2078757541 creator A5029058802 @default.
• W2078757541 creator A5035940161 @default.
• W2078757541 creator A5040860793 @default.
• W2078757541 creator A5042032194 @default.
• W2078757541 creator A5072055852 @default.
• W2078757541 creator A5091227258 @default.
• W2078757541 date "1997-11-01" @default.
• W2078757541 modified "2023-09-23" @default.
• W2078757541 title "Efficacy Of OKT3 As Primary Therapy For Histologically Confirmed Acute Renal Allograft Rejection1" @default.
• W2078757541 cites W1966729095 @default.
• W2078757541 cites W2045490787 @default.
• W2078757541 cites W2074125587 @default.
• W2078757541 cites W2076201260 @default.
• W2078757541 cites W2076632597 @default.
• W2078757541 cites W4233298376 @default.
• W2078757541 cites W4251016391 @default.
• W2078757541 doi "https://doi.org/10.1097/00007890-199711270-00009" @default.
• W2078757541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9392306" @default.
• W2078757541 hasPublicationYear "1997" @default.
• W2078757541 type Work @default.
• W2078757541 sameAs 2078757541 @default.
• W2078757541 citedByCount "12" @default.
• W2078757541 countsByYear W20787575412012 @default.
• W2078757541 crossrefType "journal-article" @default.
• W2078757541 hasAuthorship W2078757541A5026208455 @default.
• W2078757541 hasAuthorship W2078757541A5029058802 @default.
• W2078757541 hasAuthorship W2078757541A5035940161 @default.
• W2078757541 hasAuthorship W2078757541A5040860793 @default.
• W2078757541 hasAuthorship W2078757541A5042032194 @default.
• W2078757541 hasAuthorship W2078757541A5072055852 @default.
• W2078757541 hasAuthorship W2078757541A5091227258 @default.
• W2078757541 hasBestOaLocation W20787575411 @default.
• W2078757541 hasConcept C126322002 @default.
• W2078757541 hasConcept C126894567 @default.
• W2078757541 hasConcept C141071460 @default.
• W2078757541 hasConcept C2780091579 @default.
• W2078757541 hasConcept C2780306776 @default.
• W2078757541 hasConcept C2911091166 @default.
• W2078757541 hasConcept C71924100 @default.
• W2078757541 hasConcept C90924648 @default.
• W2078757541 hasConceptScore W2078757541C126322002 @default.
• W2078757541 hasConceptScore W2078757541C126894567 @default.
• W2078757541 hasConceptScore W2078757541C141071460 @default.
• W2078757541 hasConceptScore W2078757541C2780091579 @default.
• W2078757541 hasConceptScore W2078757541C2780306776 @default.
• W2078757541 hasConceptScore W2078757541C2911091166 @default.
• W2078757541 hasConceptScore W2078757541C71924100 @default.
• W2078757541 hasConceptScore W2078757541C90924648 @default.
• W2078757541 hasIssue "10" @default.
• W2078757541 hasLocation W20787575411 @default.
• W2078757541 hasLocation W20787575412 @default.
• W2078757541 hasLocation W20787575413 @default.
• W2078757541 hasOpenAccess W2078757541 @default.
• W2078757541 hasPrimaryLocation W20787575411 @default.
• W2078757541 hasRelatedWork W1486584413 @default.
• W2078757541 hasRelatedWork W2003938723 @default.
• W2078757541 hasRelatedWork W2047967234 @default.
• W2078757541 hasRelatedWork W2087086071 @default.
• W2078757541 hasRelatedWork W2117376546 @default.
• W2078757541 hasRelatedWork W2135058494 @default.
• W2078757541 hasRelatedWork W2348429519 @default.
• W2078757541 hasRelatedWork W2371369831 @default.
• W2078757541 hasRelatedWork W2439875401 @default.
• W2078757541 hasRelatedWork W3117361317 @default.
• W2078757541 hasVolume "64" @default.
• W2078757541 isParatext "false" @default.
• W2078757541 isRetracted "false" @default.
• W2078757541 magId "2078757541" @default.
• W2078757541 workType "article" @default.